The co-delivery of adjuvant is necessary for all DC targeting antibodies to avoid the induction of tolerance by DCs as demonstrated in a mouse model of AML [37], or biased CD4+ responses to a T follicular helper cell phenotype when using targeting antibodies alone [131]. The gene discussed is CD4; the disease is acute myeloid leukemia.